Article
PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.
Blood - 17 May 2018
Zhang Yingchi, Gao Yufeng, Zhang Hui, Zhang Jingliao, He Fuhong, Hnízda Aleš, Qian Maoxiang, Liu Xiaoming, Gocho Yoshihiro, Pui Ching-Hon, Cheng Tao, Wang Qianfei, Yang Jun J, Zhu Xiaofan, Liu Xin
Abstract excerpt
Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) comprises ∼10% to 15% of childhood ALL cases, many of which respond exquisitely to tyrosine kinase inhibitors (TKIs), for example, imatinib in PDGFRB-rearranged ALL. However, some cases developed drug resistance to TKIs and the mechanisms are poorly understood. In this study, we identified a novel PDGFRB fusion gene, namely AGGF1-PDGFRB, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.